|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2007-9-6
|
|
pubmed:abstractText |
The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-5472
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7945-7
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17804699-Adjuvants, Immunologic,
pubmed-meshheading:17804699-Animals,
pubmed-meshheading:17804699-Breast Neoplasms,
pubmed-meshheading:17804699-Cancer Vaccines,
pubmed-meshheading:17804699-Humans,
pubmed-meshheading:17804699-Immunotherapy,
pubmed-meshheading:17804699-Ligands,
pubmed-meshheading:17804699-Models, Biological,
pubmed-meshheading:17804699-Neoplasms,
pubmed-meshheading:17804699-Signal Transduction,
pubmed-meshheading:17804699-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:17804699-Toll-Like Receptors,
pubmed-meshheading:17804699-Vaccines, Subunit
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Toll-like receptor ligands energize peptide vaccines through multiple paths.
|
|
pubmed:affiliation |
Immunology Program and Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA. ecelis@moffitt.org
|
|
pubmed:publicationType |
Journal Article,
Review,
Evaluation Studies,
Research Support, N.I.H., Extramural
|
